The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The stability is led by healthy demand in the domestic and emerging markets
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Subscribe To Our Newsletter & Stay Updated
